Aquashunt is an implantable physiologic device that is designed to address the shortcomings of current glaucoma treatments. It is intended to reduce intraocular pressure physiologically by allowing excess fluid in the eye to exit naturally. It currently is in preclinical testing and human studies are expected to begin during the fourth quarter of 2008.
Naveed Shams, chief medical officer and senior vice president of R&D of Opko, said: “Aquashunt is designed to offer a new therapeutic option with significant benefits compared to current therapies. As a device, it also has the potential for a relatively rapid and straightforward development and regulatory pathway.”